Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.

@article{Pitrak2011BeneficialEO,
  title={Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.},
  author={David Pitrak and Randee Estes and Richard M Novak and M Linnares-Diaz and Jean M Tschampa},
  journal={AIDS research and human retroviruses},
  year={2011},
  volume={27 6},
  pages={
          659-67
        }
}
The purpose of this study was to determine if switching to an Lopinavir/ritonavir (LPV/r)-containing regimen resulted in greater immune reconstitution in patients with immunologic failure despite complete viral suppression with highly active antiretroviral therapy (HAART). Twenty patients with partial or no immune response to HAART despite viral suppression were enrolled. Ten were randomized to stay on their current regimen and 10 were randomized to LPV/r plus their current NRTI backbone. T… 
View on PubMed
indigo.uic.edu
5 Citations

5 Citations

Citation Type

Citation Type

Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery.
Investigations into apoptotic pathways, intrinsic and extrinsic, and the effects of highly active antiretroviral therapy (HAART) on T cell death via those pathways may provide insight into the…
Immune recovery and T cell subset analysis during effective treatment with maraviroc.
TLDR
The findings do not support a role for reduction in activated T cell subsets to explain the greater maraviroc-induced immune recovery, but reduction in CXCR4+CD4+ and higher expression of CCR5+ CD4+ T cells might represent a potential protection from non-R5 tropic viral strain overgrowth.
Enhanced Eryptosis Following Exposure to Lopinavir
TLDR
Lopinavir treatment of erythrocytes from healthy volunteers is followed by cell shrinkage and phospholipid scrambling of the ery Throcyte cell membrane, an effect in part due to stimulation of ROS formation and Ca2+ entry.
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
TLDR
This data indicates that conventional chemotherapy may be a viable treatment option for women with ovarian cancer, and the prognosis is good for girls aged between the ages of 18 and 29.
Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care?
  • P. Sax
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2013
TLDR
The above dialogue typifies a strange paradox of contemporary HIV clinical practice—that the authors continue to order routine monitoring of CD4 cell counts on stable patients despite not using the results for clinical decision making.

References

SHOWING 1-10 OF 53 REFERENCES
Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral—Naïve HIV-1-Infected Patients
TLDR
LPV/r-based therapy demonstrated sustained efficacy with no protease inhibitor or stavudine resistance through 7 years in antiretroviral-naïve patients.
Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides
TLDR
Late increases in CD4 cell counts, mostly owing to newly produced cells rather than redistribution, are more pronounced in therapy using a PI, especially in subjects with lower initial CD 4 cell counts.
Class-sparing regimens for initial treatment of HIV-1 infection.
TLDR
The virologic efficacy of the NRTI-sparing regimen was similar to that of the efavirenz regimen but was more likely to be associated with drug resistance.
CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
  • Richard D Moore, J. Keruly
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
TLDR
Analysis of annual change in the CD4(+) cell count for up to 6 years after the start of HAART suggests that waiting to start HAART at lower CD4 (+) cell counts will result in the cell count not returning to normal levels.
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults
TLDR
NNRTI and BPI-containing regimens offer superior virologic suppression over 48 weeks, supporting existing guidelines for the choice of initial ART and identifying the predictors of responses.
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load.
TLDR
Subcutaneous rIL-2 once a day in combination with HAART was well tolerated and improved immunologic surface markers in patients with advanced HIV infection.
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia
TLDR
Reduction in T CD4+ cell numbers may eventually occur during prolonged virologic failure of a protease inhibitor-based regimen and is predicted by the degree of virology suppression below a pre-therapy ‘set-point'.
INTERLEUKIN-2 ACCELERATES CD4 CELL RECONSTITUTION IN HIV-INFECTED PATIENTS WITH SEVERE IMMUNOSUPPRESSION DESPITE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: THE ILSTIM STUDY—ANRS 082
TLDR
The addition of interleukin-2, a cytokine that stimulates CD4 T lymphocyte helper cells, may benefit patients with discordant responses and produce significant and sustained increase in CD4 cell counts in HAART-treated patients with persistent CD4 Cell counts < 200 × 106 cells/l.
Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy
TLDR
Clinical outcomes are reported in a large cohort of patients in France 24 months after initiation of triple therapy that contained protease inhibitors, according to virologic and immunologic response at 6 months, and the long-term prognosis of patients exhibiting such discordant responses remains unknown.
Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression.
TLDR
Failure of the CD4+ cell count to increase was relatively common among antiretroviral-naive patients in the year after the initiation of HAART and the achievement of complete virus suppression, and PI-containing regimens provided better immunologic response.
...
1
2
3
4
5
...